Tianda Pharmaceuticals (HKSE:00455) LT-Debt-to-Total-Asset: 0.06 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:00455 Tianda Pharmaceuticals Ltd HKSE:00455
24 GF Score
Price HK$0.11
GF Value HK$0.13
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Tianda Pharmaceuticals LT-Debt-to-Total-Asset?

Tianda Pharmaceuticals HKSE:00455 -12.60% 24 LT-Debt-to-Total-Asset is 0.06 as of Dec. 2025. GuruFocus rates HKSE:00455 with a GF Score™ of 24/100 and a GF Value™ of HK$0.13 (Modestly Undervalued). The stock has 3 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Tianda Pharmaceuticals's long-term debt to total assests ratio for the quarter that ended in Dec. 2025 was 0.06.

Tianda Pharmaceuticals's long-term debt to total assets ratio increased from Dec. 2024 (0.00) to Dec. 2025 (0.06). It may suggest that Tianda Pharmaceuticals is progressively becoming more dependent on debt to grow their business.

Tianda Pharmaceuticals  (HKSE:00455) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Tianda Pharmaceuticals LT-Debt-to-Total-Asset Related Terms

Tianda Pharmaceuticals LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Tianda Pharmaceuticals's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tianda Pharmaceuticals LT-Debt-to-Total-Asset Chart

Tianda Pharmaceuticals Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Dec23 Dec24 Dec25
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.11 0.09 0.01 0.00 0.06

Tianda Pharmaceuticals Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.07 0.06 0.02
HKSE:00455
24GF Score
Tianda Pharmaceuticals Ltd HKSE:00455
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tianda Pharmaceuticals LT-Debt-to-Total-Asset Calculation

Tianda Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )/Total Assets (A: Dec. 2025 )
=45.989/747.825
=0.06

Tianda Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (Q: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (Q: Dec. 2025 )/Total Assets (Q: Dec. 2025 )
=45.989/747.825
=0.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.06 mean?
Tianda Pharmaceuticals (HKSE:00455) has a LT-Debt-to-Total-Asset of 0.06 as of Dec. 2025. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Tianda Pharmaceuticals and its competitors.
Is Tianda Pharmaceuticals' LT-Debt-to-Total-Asset too high?
Tianda Pharmaceuticals' current LT-Debt-to-Total-Asset is 0.06. Overall, Tianda Pharmaceuticals has a GF Score™ of 24/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Tianda Pharmaceuticals' LT-Debt-to-Total-Asset compare to ZTS?
Tianda Pharmaceuticals' LT-Debt-to-Total-Asset of 0.06 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Drug Manufacturers company?
A good LT-Debt-to-Total-Asset depends on the Drug Manufacturers industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Tianda Pharmaceuticals and its competitors. Tianda Pharmaceuticals's current LT-Debt-to-Total-Asset is 0.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tianda Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Tianda Pharmaceuticals (HKSE:00455) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$0.13, compared to a current price of HK$0.11 — trading 14.6% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.06. Tianda Pharmaceuticals' overall GF Score™ is 24/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Tianda Pharmaceuticals (HKSE:00455), the current LT-Debt-to-Total-Asset is 0.06 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Tianda Pharmaceuticals (HKSE:00455) Overvalued in 2026?

Based on GuruFocus' analysis, Tianda Pharmaceuticals stock appears to be undervalued. The current stock price of HK$0.11 is trading 14.6% below its estimated GF Value™ of HK$0.13. GuruFocus considers Tianda Pharmaceuticals to be Modestly Undervalued.

Key valuation signals for HKSE:00455:

  • LT-Debt-to-Total-Asset: 0.06
  • GF Value™: HK$0.13 vs. price of HK$0.11 (14.6% below fair value)
  • GF Score™: 24/100 with 3 warning signs

No single metric tells the full story. See the HKSE:00455 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Tianda Pharmaceuticals Business Description

Address No. 1 Tim Mei Avenue, Suites 2405-2410, 24th Floor, CITIC Tower, Central, Hong Kong, HKG
Tianda Pharmaceuticals Ltd is engaged in research and development, manufacturing, and sales of pharmaceutical, biotechnology, and healthcare products, and investment in the development of the Chinese medicine industry. The group also engages in research and development of Chinese medicine, sales of Chinese herbal medicines, traditional Chinese medicine decoction pieces and Chinese medicine, and provision of Chinese medicine clinical services. Its operating segments include the Chinese medicine business; Medical and healthcare services; and Pharmaceuticals and medical technologies business. The company derives the majority of its revenue from the Pharmaceuticals and medical technologies business. Its geographical segments include Mainland China, Hong Kong, and Australia.
24GF Score

Get the complete analysis for HKSE:00455

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$0.11
Price
HK$0.13
GF Value